Takeda Pharmaceutical Company Limited American (TAK) exhibits 41.0% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.0x enterprise multiple and 7.1% implied options volatility.
Sustained 41.0% gross profitability converts into 13.9% operating margin and 9.9% ROIC, outpacing sector cost of capital.
ROIC: 9.9% // GM: 41.0%YoY revenue trajectory of -3.3% paired with 2.21% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -3.3% // FCF YLD: 2.21%Altman Z-Score of 3.74 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.74 // F-SCORE: 7/9Trading at 32.8x trailing P/E (30.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 32.8x // EV/EBITDA: 21.0xOptions market prices a ±7.1% implied move with a 0.80 put/call ratio around $20.00 max pain.
IMPL MOVE: ±7.1% // P/C: 0.80Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 10.9% net margins.
NET MARGIN: 10.9% // D/E: 0.39x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TAK & activate live FRED threshold breach alerts.